Desirable TEG

Phase 1Small molecule

XXuanwu Hospital, Beijing

Desirable TEG is one of 44 small molecule programs targeting Vascular Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vascular DiseaseActive, not recruiting

Vascular DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Vascular Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

2 2

Repatha

Amgen

Approved

1 3

Precose

Bayer

Approved

1 4

Colcrys

Alnylam Pharmaceuticals

Letairis

Zesly

MMezzion Pharma Co. Ltd

Approved

1 7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 8

Andriol

AAuxilium

Approved

1 9

Donepezil Hydrochloride

Eisai

Approved

2 10

Kenalog

BBassett Healthcare

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vascular Disease1 trial

Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease

Unknown status·XXuanwu Hospital, Beijing·Phase 1·NCT03471169·3,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Desirable TEG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Desirable TEG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Desirable TEG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xuanwu Hospital, Beijing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: XXuanwu Hospital, Beijing

Desirable TEG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vascular Disease1 trial

References

Drug Info

Quick Facts

Related News